Please login to the form below

Not currently logged in
Email:
Password:

BMS sells APAC assets

Taisho of Japan has agreed to buy BMS' OTC portfolio in Asia Pacific and its stake in BMSI

US pharma company, Bristol-Myers Squibb (BMS) has agreed to sell its over-the-counter (OTC) assets in Asia Pacific (APAC), excluding China and Japan, to Japanese firm Taisho Pharmaceutical for $310m.

Under the deal, Taisho will acquire certain product registrations, trademarks and related assets of selected pharmaceutical and OTC products sold primarily in Indonesia, Thailand and the Philippines, as well as other Asia Pacific countries. The products include, Tempra, Counterpain, Theragran-M, Engran, Ceetrus and Keri.

The deal also includes BMS' 97.97 per cent stake in PT BMS Indonesia (BMSI) and the land, buildings, product registrations, intellectual property, fixed assets, inventory and other related assets owned by BMSI. Both companies expect the deal to complete in quarter four 2009.

All 126 permanent BMSI employees will transfer to Taisho – subject to their rights under law.

"This planned divesture is a part of BMS' strategic transformation into a more focused next-generation biopharma company that develops and commercialises products that address serious unmet medical needs," said Dieter Weinard, president, intercontinental, BMS.

"The company is looking closely at its geographic and manufacturing footprint to align more closely to the scale and size of a biopharma company," he added.

HSBC acted as exclusive financial adviser to BMS on the deal.

16th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics